前立腺肥大症日常診療マニュアル　改訂第3版

出版社： 医学図書出版
著者：
発行日： 2014-10-30
分野： 臨床医学：外科  >  泌尿器科学
ISBN： 9784865170771
電子書籍版： 2014-10-30 （改訂第3版）
書籍・雑誌
≪全国送料無料でお届け≫
取寄せ目安：8～14営業日

3,300 円(税込)

購入する
電子書籍
章別単位で購入
ブラウザ、アプリ閲覧

1,650 円(税込)

購入する

商品紹介

Fast Facts : Benign Prostatic Hyperplasia（Seventh edition）の訳書改訂第3版です。前立腺肥大症（BPH）に関する新知見が満載された1冊です。

目次

  • 前立腺肥大症日常診療マニュアル　改訂第3版

    ―目次―

    用語集
    緒言
    第1 章　病態生理
    第2 章　診断
    第3 章　内科的管理
    第4 章　伝統的外科治療の選択肢
    第5 章　低侵襲性治療の選択肢
    第6 章　治療方針決定の際に考慮すべきこと
    第7 章　BPH に関する問題点
    参考資料
    索引
    訳者追録

この書籍の参考文献

参考文献のリンクは、リンク先の都合等により正しく表示されない場合がありますので、あらかじめご了承下さい。

本参考文献は電子書籍掲載内容を元にしております。

緒言

P.10 掲載の参考文献
Girman CJ, Jacobsen SJ, Rhodes T et al. Association of health-related quality of life and benign prostatic enlargement. Eur Urol 1999 ; 35 : 277-84
 
Kirby RS. The natural history of BPH : What have we learned in the last decade? Urology 2000 ; 56 : 3-6
 

第1章 病態生理

P.21 掲載の参考文献
Arrighi H, Guess H, Metter E, Fozard J. Symptoms and signs of prostatism as risk factors for prostatectomy. Prostate 1990 ; 16 : 253-61.
PubMed
Ball AJ, Feneley RCL, Abrams PH. The natural history of untreated 'prostatism'. Br J Urol 1981 ; 533 : 613-16.
 
Berry SJ, Coffey DS, Walsh PC, Ewing LL. The development of human benign prostatic hyperplasia with age. J Urol 1984 ; 132 : 474-9.
 
Brookes S, Link C, Donovan J, McKinlay J. Relationship between lower urinary tract symptoms and erectile dysfunction : results from the Boston Area Community Health Survey. J Urol 2008 ; 179 : 250-5.
PubMed
Cathcart P, van der Meulen J, Armitage J, Emberton M. Incidence of primary and recurrent acute urinary retention between 1998 and 2003 in England. J Urol 2006 ; 176 : 200-4.
 
Coyne KS, Sexton CS, Thompson CL. The prevalence of lower urinary tract symptoms (LUTS) in the USA, the UK and Sweden : results of the Epidemiology of LUTS (EpiLUTS) study. BJU Int 2009 ; 104 : 352-60.
 
Ekman P. BPH epidemiology and risk factors. Prostate 1989 ; 2 (suppl) : 23-31.
PubMed
Garraway WM, Kirby RS. Benign prostatic hyperplasia : effects on quality of life and impact on treatment decisions. Urology 1994 ; 44 : 629-36.
PubMed
Garraway WM, McKelvie GB, Russell EBAW et al. Impact of previously unrecognised benign prostatic hyperplasia on the daily activities of middle-aged and elderly men. Br J Gen Pract 1993 ; 43 : 318-21.
 
Girman CJ, Epstein RS, Jacobsen SJ et al. Natural history of prostatism : impact of urinary symptoms on quality of life in 2115 randomly selected community men. Urology 1994 ; 44 : 825-31.
PubMed
Glynn RJ, Campion EW, Bouchard GR, Silbert JE. The development of benign prostatic hyperplasia among volunteers in the normative aging study. Am J Epidemiol 1985 ; 121 : 78-90.
PubMed
Isaacs JT, Coffey DS. Etiology and disease process of benign prostatic hyperplasia. Prostate 1989 ; 2 (suppl) : 33-50.
PubMed
Jacobsen SJ, Jacobson DJ, Girman CJ et al. Natural history of prostatism : risk factors for acute urinary retention. J Urol 1997 ; 158 : 481-7.
PubMed
Lee AJ, Russell EB, Garraway WM, Prescott RJ. Three-year follow-up of a community-based cohort of men with untreated benign prostatic hyperplasia. Eur Urol 1996 ; 30 : 11-17.
PubMed
Lukacs B, Comet D, Doublet D et al. Twoyear assessment of long-term Health-Related Quality of Life (HRQL) of 4591 patients suffering from benign prostatic hypertrophy (BPH) treated with a uroselective alpha-1 blocker, alfuzosin. J Urol 1996 ; 155 : 574A.
 
Meigs JB, Barry MJ, Giovannucci E et al. Incidence rates and risk factors for acute urinary retention : the health professionals followup study. J Urol 1999 ; 162 : 376-82.
PubMed
Mochtar CA, Kiemeney LALM, van Riemsdijk MM et al. Prostatespecific antigen as an estimator of prostate volume in the management of patients with symptomatic benign prostatic hyperplasia. Eur Urol 2003 ; 44 : 695-700.
PubMed
Roehrborn CG, Boyle P, Bergner D et al. Serum prostate-specific antigen and prostate volume predict longterm changes in symptoms and flow rate : results of a fouryear, randomized trial comparing finasteride versus placebo. PLESS Study Group. Urology 1999 ; 54 : 662-9.
 
Roehrborn CG, Malice M, Cook TJ, Girman CJ. Clinical predictors of spontaneous acute urinary retention in men with LUTS and clinical BPH : a comprehensive analysis of the pooled placebo groups of several large clinical trials. Urology 2001 ; 58 : 210-16.
PubMed
Roehrborn CG, Schwinn DA. Alpha1-adrenergic receptors and their inhibitors in lower urinary tract symptoms and benign prostatic hyperplasia. J Urol 2004 ; 171 : 1029-35.
PubMed

第2章 診断

P.36 掲載の参考文献
Abrams PH. Prostatism and prostatectomy : the value of urine flow rate measurement in the preoperative assessment for operation. J Urol 1977 ; 117 : 70-1.
PubMed
Abrams P, Cardozo L, Fall M et al. The standardisation of terminology in lower urinary tract function : report from the standardisation subcommittee of the International Continence Society. Urology 2003 ; 61 : 37-49.
 
Abrams P, Chapple C, Khoury S et al. Evaluation and treatment of lower urinary tract symptoms in older men. J Urol 2009 ; 181 : 1779-87.
 
Abrams PH, Griffiths DJ. The assessment of prostatic obstruction from urodynamic measurements and from residual urine. Br J Urol 1979 ; 51 : 129-34.
PubMed
Andriole GL, Crawford ED, Grubb RL 3rd et al. Mortality results from a randomized prostate-cancer screening trial. N Engl J Med 2009 ; 360 : 1310-9.
 
Barry MJ, Fowler FJ, O'Leary MP et al. Correlation of the American Urological Association symptom index with self administered versions of the Madsen-Iversen, Boyarsky, and Maine Medical Assessment Program symptom indexes. J Urol 1992 ; 148 : 1558-63.
 
Barry MJ, Fowler FJ, O'Leary MP et al. The American Urological Association symptom index for benign prostatic hyperplasia. J Urol 1992 ; 148 : 1549-57.
 
Benson MC, Whang IS, Panteuck A et al. Prostate specific antigen density : a means of distinguishing between benign prostatic hypertrophy and prostate cancer. J Urol 1992 ; 147 : 815-16.
PubMed
Berney DM, Gopalan A, Kudahetti S et al. Ki-67 and outcome in clinically localised prostate cancer : analysis of conservatively treated prostate cancer patients from the Trans-Atlantic Prostate Group study. Br J Cancer 2009 ; 100 : 888-93.
 
Birch NC, Hurst G, Doyle PT. Serial residual volumes in men with prostatic hypertrophy. Br J Urol 1988 ; 62 : 571-5.
PubMed
Brawer MK, Chetner MP, Beattie J et al. Screening for prostate cancer with prostate specific antigen. J Urol 1992 ; 147 : 841-5.
 
Bruskewitz RC, Iversen P, Madsen PO. Value of postvoid residual urine determination in evaluation of prostatism. Urology 1982 ; 20 : 602-4.
PubMed
Carter BH, Pearson JD, Metter J et al. Longitudinal evaluation of prostate specific antigen levels in men with and without prostate cancer. JAMA 1993 ; 267 : 2215-20.
 
Catalona WJ, Smith DS, Ratliff TL et al. Measurement of prostate specific antigen in serum as a screening test for prostate cancer. N Engl J Med 1991 ; 324 : 1156-61.
PubMed
Chancellor MB, Blaivas JG, Kaplan SA, Axelrod S. Bladder outlet obstruction versus impaired detrusor contractility : the role of uroflow. J Urol 1991 ; 145 : 810-12.
PubMed
Chisholm GD, Carne SJ, Fitzpatrick JM et al. Prostate disease : management options for the primary health team. Postgrad Med J 1995 ; 71 : 136-42.
PubMed
Crawford ED, Schutz MJ, Clejan S et al. The effect of digital rectal examination on prostate specific antigen levels. JAMA 1992 ; 267 : 2227-8.
PubMed
Drach GW, Layton TN, Binard WJ. Male peak urinary flow rate : relationship of volume voided and age. J Urol 1979 ; 122 : 210-14.
 
Gleason DM, Bottaccini MR, Drach GW, Layton TN. Urinary flow velocity as an index of male voiding function. J Urol 1982 ; 128 : 1363-7.
PubMed
Grino PB, Bruskewitz R, Blaivas JG et al. Maximum urinary flow rate by uroflowmetry : automatic or visual interpretation. J Urol 1993 ; 149 : 339-41.
PubMed
Hald T. Urodynamics in benign prostatic hyperplasia : a survey. Prostate 1989 ; 2 (suppl) : 69-77.
PubMed
Jensen KME, Jorgensen JB, Mogensen P. Urodynamics in prostatism I. Prognostic value of uroflowmetry. Scand J Urol Nephrol 1988 ; 22 : 109-17.
 
Jensen KME, Jorgensen JB, Mogensen P. Urodynamics in prostatism II. Prognostic value of pressure-flow study combined with stop-flow test. Scand J Urol Nephrol 1988 ; 114 (suppl) : 72-7.
 
Kaplan S, Garvin D, Gilhooly P et al. Impact of baseline symptom severity on future risk of benign prostatic hyperplasiarelated outcomes and long-term response to finasteride. The Pless Study Group. Urology 2000 ; 56 : 610-16.
 
Kirby RS, Chisholm G, Chapple CR et al. Shared care between general practitioners and urologists in the management of BPH : a survey of attitudes among clinicians. J R Soc Med 1995 ; 88 : 284-8.
 
Kirby RS, Fitzpatrick J, Irani J. Prostate cancer diagnosis in the new millennium : strengths and weaknesses of prostate specific antigen and the discovery and clinical evaluation of prostate cancer gene 3 (PCA3) BJU Int 2009 ; 103 : 441-5.
PubMed
McConnell JD, Barry MJ, Bruskewitz RC et al. Benign Prostatic Hyperplasia Diagnosis and Treatment. Clinical Practice Guideline No. 8. AHCPR Publication No. 940582.
 
Rockville, MD : Agency for Health Care Policy and Research, Public Health Service, US Department of Health and Human Sciences, 1994.
 
Roehrborn CG, Boyle P, Gould L, Waldstreicher J. Serum prostatespecific antigen as a predictor of prostate volume in men with benign prostatic hyperplasia. Urology 1999 ; 53 : 581-9.
 
Roehrborn CG, Malice M, Cook TJ, Girman CJ. Clinical predictors of spontaneous acute urinary retention in men with LUTS and clinical BPH : a comprehensive analysis of the pooled placebo groups of several large clinical trials. Urology 2001 : 58 ; 210-16.
PubMed
Roehrborn CG, McConnell JD, Lieber M et al. Serum prostatespecific antigen concentration is a powerful predictor of acute urinary retention and need for surgery in men with clinical benign prostatic hyperplasia. PLESS study group. Urology 1999 ; 53 : 473-80.
 
Rosen R, Altwein J, Boyle P et al. Lower urinary tract symptoms and male sexual dysfunction : the multinational survey of the ageing male (MSAM-7). Eur Urol 2003 ; 44 : 637-49.
PubMed
Schafer W, Rubben H, Noppeney R, Deutz FJ. Obstructed and unobstructed prostatic obstruction. A plea for urodynamic objectivation of bladder outflow obstruction in benign prostatic hyperplasia. World J Urol 1989 ; 6 : 198-203.
 
Schroder FH, Hugosson J, Roobol MJ et al. Screening and prostatecancer mortality in a randomized European study. N Engl J Med 2009 ; 360 : 1320-8.
 
Shoukry I, Susset JG, Elhilali MM, Dutatre D. Role of uroflowmetry in the assessment of lower urinary tract obstruction in adult males. Br J Urol 1975 ; 47 (Pt 2) : 559-66.
 
Thompson IM, Pauler DK, Goodman PJ et al. Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4.0 ng per milliliter. N Engl J Med 2004 ; 350 : 2239-46.
PubMed

第3章 内科的管理

P.55 掲載の参考文献
Abrams P, Kaplan S, De Koning Gans HJ, Millard R. Safety and tolerability of tolterodine for the treatment of overactive bladder in men with bladder outlet obstruction. J Urol 2006 ; 175 : 999-1004.
PubMed
Abrams P, Schulman C, Vaage S and the European Tamsulosin Study Group. Tamsulosin, a selective 1c-adrenoceptor antagonist : a randomized controlled trial in patients with benign prostatic 'obstruction' (symptomatic BPH). Br J Urol 1995 ; 76 : 325-36.
 
ALLHAT Collaborative Research Group. Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone : the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). JAMA 2000 ; 283 : 1967-75.
 
Andersen J, Nickel C, Marshall V et al. Finasteride significantly reduces the occurrence of acute urinary retention and surgical interventions in patients with symptomatic benign prostatic hyperplasia. Urology 1997 ; 49 : 839-45.
 
Andriole G, Bostwick D, Brawley O et al. Chemoprevention of prostate cancer in men at high risk : rationale and design of the Reduction by Dutasteride of Prostate Cancer Events (REDUCE) trial. J Urol 2004 ; 172 : 1314-17.
 
Andriole GL, Roehrborn C, Schulman C et al. Effect of dutasteride on the detection of prostate cancer in men with benign prostatic hyperplasia. Urology 2004 ; 64 : 537-41.
PubMed
Barkin J, Guimaraes M, Jacobi G et al. α-blocker therapy can be withdrawn in the majority of men following initial combination therapy with the dual 5α-reductase inhibitor dutasteride. Eur Urol 2003 ; 44 : 461-6.
 
Blake-James BT, Rashidian A, Ikeda Y, Emberton M. The role of anticholinergics in men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia : a systematic review and meta-analysis. BJU Int 2007 ; 99 : 85-96.
PubMed
Boyle P, Gould A, Roehrborn C. Prostate volume predicts outcome of treatment of benign prostatic hyperplasia with finasteride : metaanalysis of randomised clinical trials. Urology 1996 ; 48 : 398-405.
PubMed
Buzelin JM, Delauche-Cavallier MC, Roth S et al. Clinical uroselectivity : evidence from patients treated with slow-release alfuzosin for symptomatic benign prostatic obstruction. Br J Urol 1997 ; 79 : 898-906.
PubMed
Buzelin JM, Roth S, Geffriaud-Ricouard C, Delauche-Cavallier MC. Efficacy and safety of sustainedrelease alfuzosin 5 mg in patients with benign prostatic hyperplasia. Eur Urol 1997 ; 31 : 190-8.
PubMed
Chang DF, Campbell JR. Intraoperative floppy iris syndrome associated with tamsulosin. J Cataract Refract Surg 2005 ; 31 : 664-73.
PubMed
de Mey C, Michel MC, McEwen J, Moreland T. A double blind comparison of terazosin and tamsulosin on their differential effects on ambulatory blood pressure and nocturnal orthostatic stress testing. Eur Urol 1998 ; 33 : 481-8.
 
Kaplan SA, Gonzalez RR, Te AE. Combination of alfuzosin and sildenafil is superior to monotherapy in treating lower urinary tract symptoms and erectile dysfunction. Eur Urol 2007 ; 51 : 1717-23.
PubMed
Kaplan SA, Roehrborn CG, Rovner ES et al. Tolterodine and tamsulosin for treatment of men with lower urinary tract symptoms and overactive bladder : a randomized controlled trial. JAMA 2006 ; 296 : 2319-28.
PubMed
Kaplan SA, Walmsley K, Te AE. Tolterodine extended release attenuates lower urinary tract symptoms in men with benign prostatic hyperplasia. J Urol 2005 ; 174 : 2273-5.
PubMed
Kirby RS. Profile of doxazosin in hypertensive men with benign prostatic hyperplasia. Br J Clin Pract 1994 ; 54 (suppl) : 23-8.
 
Kirby RS, Roehrborn C, Boyle P et al. Efficacy and tolerability of doxazosin and finasteride, alone or in combination, in treatment of symptomatic benign prostatic hyperplasia : the PREDICT trial. Urology 2003 ; 61 : 119-26.
PubMed
Lepor H, Auerbach S, PurasBaez A et al. A randomised, placebocontrolled multicentre study of the efficacy and safety of terazosin in the treatment of benign prostatic hyperplasia. J Urol 1992 ; 148 : 1467-74.
PubMed
McConnell JD, Bruskewitz R, Walsh PC et al. The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. N Engl J Med 1998 ; 338 : 557-63.
 
McConnell JD and the PLESS Study Group. The long-term effects of finasteride on BPH : results of a fouryear, placebo-controlled study. Br J Urol 1997 ; 80 (suppl 2) : 182.
 
McConnell JD, Roehrborn CG, Bautista OM et al. The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med 2003 ; 349 : 2387-98.
 
McNeill SA. The role of alphablockers in the management of acute urinary retention caused by benign prostatic obstruction. Eur Urol 2004 ; 45 : 325-32.
 
McNeill SA, Hargreave TB, Roehrborn CG. Alfuzosin 10 mg once daily in the management of acute urinary retention : results of a double-blind placebo-controlled study. Urology 2005 ; 65 : 83-9.
PubMed
McVary KT, Siegel RL, Carlsson M. Sildenafil citrate improves erectile function and lower urinary tract symptoms independent of baseline body mass index or LUTS severity. Urology 2008 ; 72 : 575-9.
PubMed
National Institute for Health and Clinical Excellence. Lower Urinary Tract Symptoms : The Management of Lower Urinary Tract Symptoms in Men, Clinical Guideline 97.
PubMed
London : NICE, 2010. Available from http://guidance.nice.org.uk/CG97, last accessed 22 May 2011.
 
Oelke M, Bachmann A, Descazeaud A et al. Guidelines on the treatment of non-neurogenic male LUTS. European Association of Urology 2011. Available from http://www.uroweb.org/gls/pdf/12_Male_LUTS.pdf, last accessed 17 May 2011
 
O'Leary MP, Roehrborn C, Andriole G et al. Improvements in benign prostatic hyperplasia-specific quality of life with dutasteride, the novel dual 5alpha-reductase inhibitor. BJU Int 2003 ; 92 : 262-6.
PubMed
Porst H, McVary KT, Montorsi F et al. Effects of once-daily tadalafil on erectile function in men with erectile dysfunction and signs and symptoms of benign prostatic hyperplasia. Eur Urol 2009 ; 56 : 727-35.
 
Roehrborn CG, Marks LS, Fenter T et al. Efficacy and safety of dutasteride in the four-year treatment of men with benign prostatic hyperplasia. Urology 2004 ; 63 : 709-15.
PubMed
Roehrborn CG, McVary KT, Elion-Mboussa A, Viktrup L. Tadalafil administered once daily for lower urinary tract symptoms secondary to benign prostatic hyperplasia : a dose finding study. J Urol 2008 ; 180 : 1228-34.
PubMed
Roehrborn CG, Ramsdell J, Siami P. Prostate volume at baseline predicts the margin of therapeutic response with the 5α-reductase inhibitor dutasteride. J Urol 2002 ; 167 : 373A.
 
Roehrborn CG, Siami P, Barkin J et al. The effects of combination therapy with dutasteride and tamsulosin on clinical outcomes in men with symptomatic benign prostatic hyperplasia : 4-year results from the CombAT study. Eur Urol 2010 ; 57 : 123-131.
 
Roehrborn CG, Siami P, Barkin J et al. The effects of dutasteride, tamsulosin and combination therapy on lower urinary tract symptoms in men with benign prostatic hyperplasia and prostatic obstruction : results from the CombAT Study. J Urol 2008 ; 179 : 616-21.
 
Speakman MJ, Kirby RS, Joyce A et al. Guideline for the primary care management of male lower urinary tract symptoms. BJU Int 2004 ; 93 : 985-90.
PubMed
Stief CG, Porst H, Neuser D et al. A randomised, placebo-controlled study to assess the efficacy of twice-daily vardenafil in the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia. Eur Urol 2008 ; 53 : 1236-44.
PubMed
Tanguay S, Awde H, Brock G et al. Diagnosis and management of benign prostatic hyperplasia in primary care. Can Urol Assoc J 2009 ; 3 (suppl 2) : S92-100.
 
Thompson IM, Goodman PJ, Tangen CM et al. The influence of finasteride on the development of prostate cancer. N Engl J Med 2003 ; 349 : 215-24.
PubMed

第4章 伝統的外科治療の選択肢

P.64 掲載の参考文献
Abrams PH, Farrar DJ, Turner Warwick RT et al. The results of prostatectomy : a symptomatic and urodynamic analysis of 152 patients. J Urol 1979 ; 121 : 640-2.
PubMed
Brookes ST, Donovan JL, Peters TJ et al. Sexual dysfunction in men after treatment for lower urinary tract symptoms : evidence from randomised controlled trial. BMJ 2002 ; 324 : 1059-61.
PubMed
Bruskewitz RC, Larsen EH, Madsen PO, Dorflinger T. 3-year follow-up of urinary symptoms after transurethral resection of the prostate. J Urol 1986 ; 136 : 613-15.
 
Emberton M, Black N, Blandy JP et al. The effectiveness of prostatectomy in reducing symptoms and improving quality of life in 5131 men. J Urol 1995 ; 153 : 317A.
 
Holtgrewe HL, Valk WL. Factors influencing mortality and morbidity of transurethral prostatectomy : a study of 2013. J Urol 1962 ; 87 : 450-549.
 
Larsen EH, Dorflinger T, Gasser TC et al. Transurethral incision versus transurethral resection of the prostate for the treatment of benign prostatic hypertrophy. A preliminary report. Scand J Urol Nephrol 1987 ; 104 : 83-6.
 
Mebust WK, Holtgrewe HL, Cockett ATK. Transurethral prostatectomy : immediate and postoperative complications : a cooperative study of 13 participating institutions evaluating 3885 patients. J Urol 1989 ; 141 : 243-7.
 
Oelke M, Bachmann A, Descazeaud A et al. Guidelines on the Treatment of Non-neurogenic Male LUTS. European Association of Urology 2011. Available from http://www.uroweb.org/gls/pdf/12_Male_LUTS.pdf, last accessed 17 May 2011.
 
Roos NP, Ramsey EW. A population based study of prostatectomy : outcomes associated with differing surgical approaches. J Urol 1987 ; 137 : 1184-8.
PubMed
Roos NP, Wennberg JE, Malenka DJ et al. Mortality and reoperation after open and transurethral resection of the prostate for benign prostatic hyperplasia. N Engl J Med 1989 ; 320 : 1120-4.
PubMed
Wasson JH, Bubolz TA, Lu-Yao GL et al. Transurethral resection of the prostate among medicare beneficiaries : 1984 to 1997. For the Patient Outcomes Research Team for Prostatic Diseases. J Urol 2000 ; 164 : 1212-15.
 
Wasson JH, Reda DJ, Bruskewitz RC et al. A comparison of transurethral surgery with watchful waiting for moderate symptoms of benign prostatic hyperplasia. N Engl J Med 1995 ; 332 : 75-9.
PubMed

第5章 低侵襲性治療の選択肢

P.71 掲載の参考文献
d'Ancona FCH, Francisca EAE, Hendriks JCM et al. High energy transurethral thermotherapy in the treatment of benign prostatic hyperplasia : criteria to predict outcome. Prost Cancer Prost Dis 1999 ; 2 : 98-105.
 
Chacko KN, Donovan JL, Abrams P et al. Transurethral prostatic resection or laser therapy for men with acute urinary retention : the ClasP randomized trial. J Urol 2001 ; 166 : 166-70.
 
De La Rosette J, Wildt M, Hofner K et al. High energy thermotherapy in the treatment of benign prostatic hyperplasia : results of the European benign prostatic hyperplasia study group. J Urol 1996 ; 156 : 97-102.
 
Donatucci C, Donohue R, Berger N et al. Randomized clinical trial comparing balloon dilatation to transurethral resection of prostate for benign prostatic hyperplasia. Urology 1993 ; 42 : 42-9.
PubMed
Gilling P. Holmium laser enucleation of the prostate (HoLEP). BJU Int 2008 ; 101 : 131-42.
PubMed
Gilling PJ, Aho TF, Frampton CM et al. Holmium laser enucleation of the prostate : results at 6 years. Eur Urol 2008 ; 53 : 744-9.
PubMed
Gilling PJ, Fraundorfer MR. Holmium laser prostatectomy : a technique in evolution. Curr Opin Urol 1998 ; 8 : 11-15.
PubMed
Hoffman RM, Macdonald R, Slaton JW et al. Laser prostatectomy versus transurethral resection for treating benign prostatic obstruction : a systematic review. J Urol 2003 ; 169 : 210-15.
PubMed
Issa MM. Transurethral needle ablation of the prostate : report of initial United States clinical trial. J Urol 1996 ; 156 : 413-19.
PubMed
Kaplan SA. Expanding the role of photoselective vaporization of the prostate. Rev Urol 2006 ; 8 (suppl 3) : S3-8.
 
Kaplan SA, Blute M, Bruskewitz RC et al. Long-term efficacy and durability in 345 patients treated with transurethral microwave thermotherapy for benign prostatic hyperplasia : five-year results. J Urol 2001 ; 167 : 292A.
 
Kuo RL, Kim SC, Lingeman JE et al. Holmium laser enucleation of prostate (HoLEP) : the Methodist Hospital experience with greater than 75 gram enucleations. J Urol 2003 ; 170 : 149-52.
PubMed
Lepor H, Sypherd D, Machi G, Derus J. Randomized double blind study comparing the effectiveness of balloon dilatation of the prostate and cystoscopy for the treatment of symptomatic benign prostatic hyperplasia. J Urol 1992 ; 147 : 639-44.
PubMed
McAllister WJ, Karim O, Plail RO et al. Transurethral electrovaporization of the prostate : is it any better than conventional transurethral resection of the prostate? BJU Int 2003 ; 91 : 211-4.
PubMed
Noble SM, Coast J, Brookes S et al. Transurethral prostate resection, noncontact laser therapy or conservative management in men with symptoms of benign prostatic enlargement? An economic evaluation. J Urol 2002 ; 168 : 2476-82.
PubMed
Oelke M, Bachmann A, Descazeaud A et al. Guidelines on the treatment of non-neurogenic male LUTS. European Association of Urology 2011. Available from www.uroweb.org/gls/pdf/12_Male_LUTS.pdf, last accessed 17 May 2011.
 
Oxford Centre for Evidence-based Medicine. Levels of evidence (March 2009). Available from http://www.cebm.net/index.aspx?o=1025, last accessed 17 May 2011.
 
Rosario D, Woo H, Byrne L et al. 12-month follow-up of the safety and efficacy of TransUrethral Needle Ablation (TUNA). J Urol 1996 ; 155 : 705A.
 
Tan AH, Gilling PJ, Kennett KM et al. A randomized trial comparing holmium laser enucleation of the prostate with transurethral resection of the prostate for the treatment of bladder outlet obstruction secondary to benign prostatic hyperplasia in large glands (40 to 200 grams). J Urol 2003 ; 170 : 1270-4.
 
Tewari A, Narayan P. Electrovaporisation of the prostate. Br J Urol 1996 ; 78 : 667-76.
 
Yang Q, Peters TJ, Donovan JL et al. Transurethral incision compared with transurethral resection of the prostate for bladder outlet obstruction : a systematic review and meta-analysis of randomized controlled trials. J Urol 2001 ; 165 : 1526-32.
PubMed
Zlotta AR, Giannakopoulos X, Maehlum O et al. Long-term evaluation of transurethral needle ablation of the prostate (TUNA) for treatment of symptomatic benign prostatic hyperplasia : clinical outcome up to five years from three centers. Eur Urol 2003 ; 44 : 89-93.
PubMed

第6章 治療方針決定の際に考慮すべきこと

P.80 掲載の参考文献
American Urological Association. AUA guideline on management of benign prostatic hyperplasia (2003). J Urol 2003 ; 170 : 530-47.
 
Brookes ST, Donovan JL, Peters TJ et al. Sexual dysfunction in men after treatment for lower urinary symptoms : evidence from randomised controlled trial. BMJ 2002 ; 324 : 1059-61.
PubMed
Brown CT, Yap T, Cromwell DA et al. Self management for men with lower urinary tract symptoms : randomised controlled trial. BMJ 2007 ; 334 : 25.
PubMed
Johnson NJ, Kirby RS. Treatments for benign prostatic hyperplasia : an analysis of their clinical and economic impact in the UK and Italy. J Outcomes Res 1999 ; 3 : 11-26.
 
Kaplan SA, DE Rose AF, Kirby RS et al. Beneficial effects of extendedrelease doxazosin and doxazosin standard on sexual health. BJU Int 2006 ; 97 : 559-66.
PubMed
Kohler T, McVary K. The relationship between erectile dysfunction and lower urinary tract symptoms and the role of phosphodiesterase type 5 inhibitors. Eur Urol 2009 ; 55 : 38-48.
PubMed
McConnell JD, Bruskewitz R, Walsh PC et al. The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. Finasteride Long-Term Efficacy and Safety Study Group. N Engl J Med 1998 ; 338 : 557-63.
 
McVary KT, Siegel RL, Carlsson M. Sildenafil citrate improves erectile function and lower urinary tract symptoms independent of baseline body mass index or LUTS severity. Urology 2008 ; 72 : 575-9.
PubMed
Porst H, McVary KT, Montorsi F et al. Effects of once-daily tadalafil on erectile function in men with erectile dysfunction and signs and symptoms of benign prostatic hyperplasia. Eur Urol 2009 ; 56 : 727-35.
 
Roehrborn C, Boyle P, Nickel J et al. ARIA3001 ARIA3002 and ARIA3003 Study Investigators. Efficacy and safety of a dual inhibitor of 5-alpha-reductase types 1 and 2 (dutasteride) in men with benign prostatic hyperplasia. Urology 2002 ; 60 : 434-41.
 
Roehrborn CG, McVary KT, Elion-Mboussa A, Viktrup L. Tadalafil administered once daily for lower urinary tract symptoms secondary to benign prostatic hyperplasia : a dose finding study. J Urol 2008 ; 180 : 1228-34.
PubMed
Rosen R, Altwein J, Boyle P et al. Lower urinary tract symptoms and male sexual dysfunction : the multinational survey of the aging male (MSAM-7). Eur Urol 2003 ; 44 : 637-49.
PubMed
Rosen RC, Wei JT, Althof SE et al. Association of sexual dysfunction with lower urinary tract symptoms of BPH and BPH medical therapies : results from the BPH Registry. Urology 2009 ; 73 : 562-6.
PubMed
van Moorselaar RJ, Hartung R, Emberton M et al. Alfuzosin 10 mg once daily improves sexual function in men with lower urinary tract symptoms and concomitant sexual dysfunction. BJU Int 2005 ; 95 : 603-8.
PubMed

第7章 BPHに関する問題点

P.85 掲載の参考文献
Kirby RS.The urologist as the advocate of men's health. BJU Int 2005 ; 95 : 929.
PubMed
Kirby RS, Kirby MG. The urologist as an advocate of men's health : 10 suggested steps toward helping patients achieve better overall health. Urology 2005 ; 66 (suppl) : 52-6.
 
Rosenberg MT, Staskin DR, Kaplan SA et al. A practical guide to the evaluation and treatment of male lower urinary tract symptoms in the primary care setting. Int J Clin Pract 2007 ; 61 : 1535-46.
 

参考資料

P.86 掲載の参考文献
AUA 2010 : www.auanet.org/content/guidelines-and-quality-care/clinical-guidelines.cfm?sub=bph (2010)
 
AUA 2003 (now archived) : www.auanet.org/content/guidelines-and-quality-care/clinical-guidelines/archived-guidelines/bph-archive.cfm
 
EAU 2011 : www.uroweb.org/gls/pdf/12_Male_LUTS.pdf
 
NICE 2010 : http://guidance.nice.org.uk/CG97
 
Speakman MJ, Kirby RS, Joyce A et al. The British Association of Urological Surgeons. Guideline for the primary care management of lower urinary tract symptoms. BJU Int 2004 ; 93 : 985-90.
PubMed

訳者追録

P.93 掲載の参考文献
1) Barry MJ et al : J Urol 148 ; 1549-1557, 1992
PubMed
2) Masumori et al : BJU Int 95 ; 1013-1022, 2005
PubMed
3) 前立腺肥大症ガイドライン : 日本泌尿器科学会/編, 2011
 
P.97 掲載の参考文献
1) Roehborn CG et al : Urology 60 (3) ; 434-441, 2002
 
2) Andriole GL et al : J Urol 175 (5) ; 1662-2006, 2006
 
3) Marks LS et al : J Urol 176 (3) ; 868-874, 2006
PubMed
4) Choo R et al : Prostate 67 (15) ; 1614-1620, 2007
PubMed
5) Lucia MS et al : J Natl Cancer Inst 99 (18) ; 1375-1383, 2007
PubMed
6) Tsukamoto T et al : Int J Urol 16 (9) ; 745-750, 2009
PubMed
7) Elliott CS et al : Cancer Res 15 (14) ; 4694-4699, 2009
PubMed
8) Andriole GL et al : N Engl J Med 362 (13) ; 1192-1202, 2010
PubMed
9) Andriole GL et al : J Urol 185 (1) ; 126-131, 2011
PubMed
10) Roehrborn CG et al : Eur Urol 59 (2) ; 244-249, 2011
PubMed
11) Fleshner N et al : Lancet 379 (9821) ; 1103-1111, 2012
PubMed
P.103 掲載の参考文献
1) Burnet Al et al : Urology 45 (3) ; 435-439, 1995
 
2) Takeda M et al : Urology 45 (3) ; 440-446, 1995
PubMed
3) Fazio L et al : CMAJ 170 (9) ; 1429-1437, 2004
PubMed
4) McVary K : BJU Int 97 Supple 2 ; 23-28, 2006
 
5) 前立腺肥大症診療ガイドライン 日本泌尿器科学会/編, 2011
 
6) Morelli A et al : J Sex Med 8 (10) ; 2746-2760, 2011
 
7) Angulo J et al : J Sex Med 9 (9) ; 2293-2306, 2012
 
8) Werkstrom V et al : BJU Int 98 (2) ; 414-423, 2012
 
9) Minagawa T et al : BJU Int 110 (6PtB) ; E259-E266, 2012
 
10) Morelli A et al : Prostate 73 (4) ; 428-441, 2013
PubMed
11) Casabe A et al : J Urology 131 (3) ; 727-733, 2014
 

書評

最近チェックした商品履歴

Loading...